Aerovate Therapeutics Files Amendment on Exit Costs
Ticker: JBIO · Form: 8-K/A · Filed: Jul 1, 2024 · CIK: 1798749
Sentiment: neutral
Topics: amendment, restructuring, disposal-costs
TL;DR
Aerovate filed an update on exit costs, details TBD.
AI Summary
Aerovate Therapeutics, Inc. filed an amendment (8-K/A) on July 1, 2024, to its previous report dated June 25, 2024. This amendment pertains to costs associated with exit or disposal activities. The filing does not disclose specific dollar amounts or detailed reasons for these costs.
Why It Matters
This amendment indicates potential restructuring or discontinuation of certain operations within Aerovate Therapeutics, which could impact future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially concerning exit or disposal activities, can signal significant operational changes or financial distress, warranting closer scrutiny.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- June 25, 2024 (date) — Date of earliest event reported
- July 1, 2024 (date) — Date of report (filing date)
- 001-40544 (other) — SEC File Number
- 83-1377888 (other) — I.R.S. Employer Identification No.
FAQ
What specific exit or disposal activities are being reported by Aerovate Therapeutics?
The filing is an amendment (8-K/A) to report costs associated with exit or disposal activities, but it does not specify the nature of these activities.
When was the original event related to these costs reported?
The earliest event reported in the amendment was on June 25, 2024.
What is the filing date of this amendment?
The amendment was filed on July 1, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
What is the company's telephone number?
The company's telephone number is (617) 443-2400.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-07-01 16:03:32
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
- $5.6 m — ideration of releases) of approximately $5.6 million, which are primarily one-time sev
Filing Documents
- tmb-20240625x8ka.htm (8-K/A) — 53KB
- 0001798749-24-000039.txt ( ) — 175KB
- tmb-20240625.xsd (EX-101.SCH) — 3KB
- tmb-20240625_lab.xml (EX-101.LAB) — 16KB
- tmb-20240625_pre.xml (EX-101.PRE) — 11KB
- tmb-20240625x8ka_htm.xml (XML) — 5KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On June 25, 2024, Aerovate Therapeutics, Inc. (the "Company") determined to implement a reduction of the Company's workforce (the "Workforce Reduction Plan") following the Company's previously announced decision to shut down its Phase 2b/Phase 3 clinical trial of AV-101 as well as the long-term extension study. Under the Workforce Reduction Plan, the Company intends that nearly all of its workforce will be terminated in the coming months. The Company initiated the first wave of its Workforce Reduction Plan by notifying 39 individuals, or 78% of the Company's workforce, of their termination. The affected individuals will be provided severance benefits, including cash severance payments. Each affected individual's eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company estimates that it will be incurring costs (in consideration of releases) of approximately $5.6 million, which are primarily one-time severance benefits. These costs are expected to be incurred in the third and fourth quarter of 2024. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "future," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," seek," "strategy," "should," "target," "will," "would" and similar expressions regarding future periods. These forward-looking statements include, but are not limited to, statements regarding the estimated costs expected to be incurred in connection with the Workforce Reduction Plan and related severance payments. Any fo